Verve Therapeutics experienced a rise in its stock for the second consecutive session on Tuesday following an upgrade by Cantor Fitzgerald. This upgrade was a response to early-stage trial data released by the gene editing company for its cholesterol therapy, VERVE-102. Verve’s stock saw a significant increase, closing 26% higher.
Verve Stock Upgraded by Cantor Fitzgerald; Shares Rise (VERV:NASDAQ)
Date: